Vijaytha Muralidharan
Hidradenitis suppurativa (HS) is a chronic relapsing and remitting condition which is characterised by inflammation resulting in painful nodules and abscesses and can prove difficult to treat, especially as patients experience social and psychological complexities. HS is traditionally managed with lifestyle modifications and antibiotics. Introduction of biologic therapy has revolutionised treatment, with benefits in reducing pain, discharge and nodule recurrence.
Adalimumab is a monoclonal antibody used for resistant cases of HS. Multiple studies have shown remarkable clinical efficacy of Adalimumab in reducing the severity of physical symptoms, but few have explored in depth the psychological and social effects of the drug.
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi